Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREV-HOSPIT pneumococcal vaccination during acute febrile illness in hospitalized adults
2024-517411-73-00Phase 4Authorised
- Sponsor
- CHU Saint-Etienne
- Start
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in invasive pneumococcal disease (IPD) comparing Capvaxive arm with Prevenar 20 arm (2 arms). Primary endpoints: Proportion of immune good responders at 1 month after vaccination and Alternative immune good responder definition at 1 month after vaccination. Planned start Nov 2025; status: authorised.
02
Drugs
PCV21Prevnar 20
03
Conditions
invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on 2024-517411-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517411-73-00.